Consequently, given that NPM1 mutations are among the most common mutations in AML and are well-established as prognostic markers [1, 2], the question of whether STMs alter the prognostic value of NPM1 is of great clinical interest. The gene discussed is NPM1; the disease is acute myeloid leukemia.